Latest Lead News

oOh!media Limited reported a robust first half in 2025 with 17% revenue growth and a 27% rise in underlying EBITDA, driven by key contract wins and operational efficiencies. Despite a $30 million impairment in New Zealand, the company declared a fully franked interim dividend and outlined a positive outlook with a CEO transition on the horizon.

oOh!media Limited reported a robust 17% increase in revenue for the first half of 2025, driven by strong Australian market segments, but posted a statutory loss due to a significant impairment charge in New Zealand. The company also announced a restructuring and a new CEO appointment.

The GPT Group has delivered a robust 2025 interim result, reporting solid income growth and a strong balance sheet, while announcing a significant equity raise to fuel future expansion.

The a2 Milk Company reported a robust 13.5% revenue increase and a 21.1% rise in net profit for the fiscal year ending June 2025, alongside healthy dividend declarations.

The GPT Group has reported a remarkable turnaround in its half-year results, with revenues soaring over 1000% and net profit swinging from a loss to a substantial gain, prompting a solid distribution declaration.

MC Mining has officially begun open pit mining at its flagship Makhado hard coking coal project in South Africa, advancing steadily towards full production by year-end 2025.

Lowell Resources Fund (ASX, LRT) reported a stellar FY2025 with net assets soaring 72.5% to $72.3 million and profits jumping over 1400%, driven by strong gold and precious metals exposure.

WAM Leaders Limited has raised its fully franked full year dividend to 9.4 cents per share despite underperforming the ASX 200 in FY2025, signaling confidence in a market inflection and a strategic pivot towards quality and growth sectors.

WAM Global Limited outperformed the MSCI World Index in FY2025 with a 19.4% portfolio gain, enabling a higher fully franked dividend of 17 cents per share. The company’s strong results reflect strategic investments in undervalued global growth stocks amid volatile markets.

Neurizon Therapeutics faces a delay in FDA review for its lead ALS therapy NUZ-001, with a new decision expected by early October amid agency-wide staffing challenges.

WA1 Resources has raised A$100 million through a placement to accelerate pre-development and infrastructure work at its Luni Niobium Project, bolstering its cash reserves to A$168 million.

EMVision Medical Devices has been awarded a $3 million non-dilutive government grant to conduct a pioneering clinical study using its telehealth-enabled emu™ brain scanner in regional South Australia, aiming to transform stroke diagnosis and treatment.